Corcept Therapeutics Crecimiento futuro
Future controles de criterios 6/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Corcept Therapeutics de 48.7% y 21.7% por año respectivamente. Se prevé que el BPA crezca en un 49.6% al año. Se espera que la rentabilidad financiera sea de 31.5% en 3 años.
Información clave
48.7%
Tasa de crecimiento de los beneficios
49.62%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.4% |
| Tasa de crecimiento de los ingresos | 21.7% |
| Rentabilidad financiera futura | 31.46% |
| Cobertura de analistas | Low |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking AlphaCORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 1,550 | 534 | 225 | 490 | 5 |
| 12/31/2027 | 1,290 | 253 | 132 | 302 | 5 |
| 12/31/2026 | 989 | 84 | 108 | 150 | 5 |
| 3/31/2026 | 769 | 47 | 120 | 120 | N/A |
| 12/31/2025 | 761 | 98 | 142 | 142 | N/A |
| 9/30/2025 | 741 | 105 | 163 | 163 | N/A |
| 6/30/2025 | 716 | 132 | 180 | 182 | N/A |
| 3/31/2025 | 685 | 133 | 177 | 179 | N/A |
| 12/31/2024 | 675 | 140 | 196 | 198 | N/A |
| 9/30/2024 | 629 | 140 | 142 | 144 | N/A |
| 6/30/2024 | 570 | 125 | 123 | 124 | N/A |
| 3/31/2024 | 524 | 117 | 125 | 125 | N/A |
| 12/31/2023 | 482 | 105 | 127 | 127 | N/A |
| 9/30/2023 | 450 | 91 | 154 | 155 | N/A |
| 6/30/2023 | 428 | 94 | 135 | 135 | N/A |
| 3/31/2023 | 414 | 94 | 111 | 111 | N/A |
| 12/31/2022 | 402 | 101 | 120 | 120 | N/A |
| 9/30/2022 | 398 | 117 | 136 | 136 | N/A |
| 6/30/2022 | 392 | 113 | 151 | 151 | N/A |
| 3/31/2022 | 380 | 112 | 177 | 178 | N/A |
| 12/31/2021 | 366 | 113 | 167 | 168 | N/A |
| 9/30/2021 | 353 | 106 | 153 | 154 | N/A |
| 6/30/2021 | 343 | 98 | 134 | 135 | N/A |
| 3/31/2021 | 340 | 99 | 143 | 144 | N/A |
| 12/31/2020 | 354 | 106 | 151 | 152 | N/A |
| 9/30/2020 | 356 | 109 | 164 | 165 | N/A |
| 6/30/2020 | 351 | 114 | 173 | 173 | N/A |
| 3/31/2020 | 335 | 106 | 145 | 146 | N/A |
| 12/31/2019 | 306 | 94 | N/A | 136 | N/A |
| 9/30/2019 | 285 | 87 | N/A | 109 | N/A |
| 6/30/2019 | 268 | 78 | N/A | 115 | N/A |
| 3/31/2019 | 258 | 76 | N/A | 105 | N/A |
| 12/31/2018 | 251 | 75 | N/A | 116 | N/A |
| 9/30/2018 | 238 | 152 | N/A | 119 | N/A |
| 6/30/2018 | 216 | 148 | N/A | 85 | N/A |
| 3/31/2018 | 189 | 142 | N/A | 86 | N/A |
| 12/31/2017 | 159 | 129 | N/A | 61 | N/A |
| 9/30/2017 | 130 | 35 | N/A | 41 | N/A |
| 6/30/2017 | 109 | 24 | N/A | 39 | N/A |
| 3/31/2017 | 93 | 13 | N/A | 25 | N/A |
| 12/31/2016 | 81 | 8 | N/A | 18 | N/A |
| 9/30/2016 | 72 | 5 | N/A | 18 | N/A |
| 6/30/2016 | 64 | 1 | N/A | 10 | N/A |
| 3/31/2016 | 56 | -2 | N/A | 8 | N/A |
| 12/31/2015 | 50 | -6 | N/A | 3 | N/A |
| 9/30/2015 | 44 | -11 | N/A | -2 | N/A |
| 6/30/2015 | 38 | -17 | N/A | -9 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (48.7% al año) de CORT es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (48.7% al año) de CORT crezcan más rápidamente que el mercado US (16.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de CORT crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (21.7% al año) de CORT crezcan más rápidamente que los del mercado US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (21.7% al año) de CORT crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de CORT sea alta dentro de 3 años (31.5%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 06:15 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Corcept Therapeutics Incorporated está cubierta por 18 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |